Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 6 minute read Pharma Industry News Can Protagonist’s icotrokinra become the first oral IL-23 therapy to rival biologics in ulcerative colitis? Positive Phase 2b data for Protagonist Therapeutics’ oral IL-23R inhibitor icotrokinra show strong efficacy and safety in ulcerative colitis; learn what’s next for Phase 3. byVenkateshOctober 10, 2025